Literature DB >> 26481147

A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.

Robert W Schnepp1, Priya Khurana1, Edward F Attiyeh2, Pichai Raman3, Sara E Chodosh1, Derek A Oldridge1, Maria E Gagliardi1, Karina L Conkrite1, Shahab Asgharzadeh4, Robert C Seeger4, Blair B Madison5, Anil K Rustgi6, John M Maris7, Sharon J Diskin8.   

Abstract

A more complete understanding of aberrant oncogenic signaling in neuroblastoma, a malignancy of the developing sympathetic nervous system, is paramount to improving patient outcomes. Recently, we identified LIN28B as an oncogenic driver in high-risk neuroblastoma. Here, we identify the oncogene RAN as a LIN28B target and show regional gain of chromosome 12q24 as an additional somatic alteration resulting in increased RAN expression. We show that LIN28B influences RAN expression by promoting RAN Binding Protein 2 expression and by directly binding RAN mRNA. Further, we demonstrate a convergence of LIN28B and RAN signaling on Aurora kinase A activity. Collectively, these findings demonstrate that LIN28B-RAN-AURKA signaling drives neuroblastoma oncogenesis, suggesting that this pathway may be amenable to therapeutic targeting.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26481147      PMCID: PMC4643330          DOI: 10.1016/j.ccell.2015.09.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  67 in total

1.  Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models.

Authors:  Liem H Nguyen; Daisy A Robinton; Marc T Seligson; Linwei Wu; Lin Li; Dinesh Rakheja; Sarah A Comerford; Saleh Ramezani; Xiankai Sun; Monisha S Parikh; Erin H Yang; John T Powers; Gen Shinoda; Samar P Shah; Robert E Hammer; George Q Daley; Hao Zhu
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

2.  Prognostic impact of gene expression-based classification for neuroblastoma.

Authors:  André Oberthuer; Barbara Hero; Frank Berthold; Dilafruz Juraeva; Andreas Faldum; Yvonne Kahlert; Shahab Asgharzadeh; Robert Seeger; Paola Scaruffi; Gian Paolo Tonini; Isabelle Janoueix-Lerosey; Olivier Delattre; Gudrun Schleiermacher; Jo Vandesompele; Joëlle Vermeulen; Frank Speleman; Rosa Noguera; Marta Piqueras; Jean Bénard; Alexander Valent; Smadar Avigad; Isaac Yaniv; Axel Weber; Holger Christiansen; Richard G Grundy; Katharina Schardt; Manfred Schwab; Roland Eils; Patrick Warnat; Lars Kaderali; Thorsten Simon; Boris Decarolis; Jessica Theissen; Frank Westermann; Benedikt Brors; Matthias Fischer
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 44.544

Review 3.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

4.  Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras.

Authors:  Jee-Sun Oh; Jae-Jin Kim; Ju-Yeon Byun; In-Ah Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

5.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer.

Authors:  Aurora Esquela-Kerscher; Phong Trang; Jason F Wiggins; Lubna Patrawala; Angie Cheng; Lance Ford; Joanne B Weidhaas; David Brown; Andreas G Bader; Frank J Slack
Journal:  Cell Cycle       Date:  2008-03-03       Impact factor: 4.534

6.  LIN28 binds messenger RNAs at GGAGA motifs and regulates splicing factor abundance.

Authors:  Melissa L Wilbert; Stephanie C Huelga; Katannya Kapeli; Thomas J Stark; Tiffany Y Liang; Stella X Chen; Bernice Y Yan; Jason L Nathanson; Kasey R Hutt; Michael T Lovci; Hilal Kazan; Anthony Q Vu; Katlin B Massirer; Quaid Morris; Shawn Hoon; Gene W Yeo
Journal:  Mol Cell       Date:  2012-09-06       Impact factor: 17.970

7.  Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Authors:  John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

8.  Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.

Authors:  Mario Capasso; Marcella Devoto; Cuiping Hou; Shahab Asgharzadeh; Joseph T Glessner; Edward F Attiyeh; Yael P Mosse; Cecilia Kim; Sharon J Diskin; Kristina A Cole; Kristopher Bosse; Maura Diamond; Marci Laudenslager; Cynthia Winter; Jonathan P Bradfield; Richard H Scott; Jayanti Jagannathan; Maria Garris; Carmel McConville; Wendy B London; Robert C Seeger; Struan F A Grant; Hongzhe Li; Nazneen Rahman; Eric Rappaport; Hakon Hakonarson; John M Maris
Journal:  Nat Genet       Date:  2009-05-03       Impact factor: 38.330

9.  The microRNA.org resource: targets and expression.

Authors:  Doron Betel; Manda Wilson; Aaron Gabow; Debora S Marks; Chris Sander
Journal:  Nucleic Acids Res       Date:  2007-12-23       Impact factor: 16.971

10.  Selective blockade of microRNA processing by Lin28.

Authors:  Srinivas R Viswanathan; George Q Daley; Richard I Gregory
Journal:  Science       Date:  2008-02-21       Impact factor: 47.728

View more
  52 in total

1.  LIN28B: an orchestrator of oncogenic signaling in neuroblastoma.

Authors:  Robert W Schnepp; Sharon J Diskin
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

2.  LncRNA H19-elevated LIN28B promotes lung cancer progression through sequestering miR-196b.

Authors:  Jin Ren; Jinling Fu; Tiangang Ma; Bingdi Yan; Rong Gao; Zhe An; Dan Wang
Journal:  Cell Cycle       Date:  2018-07-23       Impact factor: 4.534

3.  Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.

Authors:  Veronica Veschi; Zhihui Liu; Ty C Voss; Laurent Ozbun; Berkley Gryder; Chunhua Yan; Ying Hu; Anqi Ma; Jian Jin; Sharlyn J Mazur; Norris Lam; Barbara K Souza; Giuseppe Giannini; Gordon L Hager; Cheryl H Arrowsmith; Javed Khan; Ettore Appella; Carol J Thiele
Journal:  Cancer Cell       Date:  2017-01-09       Impact factor: 31.743

4.  Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

Authors:  Steven G DuBois; Yael P Mosse; Elizabeth Fox; Rachel A Kudgus; Joel M Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M Maris; Clare J Twist; Kelly Goldsmith; M Meaghan Granger; Brian Weiss; Julie R Park; Margaret E Macy; Susan L Cohn; Greg Yanik; Lars M Wagner; Randall Hawkins; Jesse Courtier; Hollie Lai; Fariba Goodarzian; Hiroyuki Shimada; Najee Boucher; Scarlett Czarnecki; Chunqiao Luo; Denice Tsao-Wei; Katherine K Matthay; Araz Marachelian
Journal:  Clin Cancer Res       Date:  2018-08-09       Impact factor: 12.531

5.  Germline 16p11.2 Microdeletion Predisposes to Neuroblastoma.

Authors:  Laura E Egolf; Zalman Vaksman; Gonzalo Lopez; Jo Lynne Rokita; Apexa Modi; Patricia V Basta; Hakon Hakonarson; Andrew F Olshan; Sharon J Diskin
Journal:  Am J Hum Genet       Date:  2019-08-29       Impact factor: 11.025

6.  MicroRNA-4458 suppresses the proliferation of human lung cancer cells in vitro by directly targeting Lin28B.

Authors:  Chang-Hong Liu; De-Sheng Lv; Mo Li; Ge Sun; Xue-Fei Zhang; Yu Bai
Journal:  Acta Pharmacol Sin       Date:  2017-06-12       Impact factor: 6.150

7.  MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Authors:  Steven G DuBois; Rajen Mody; Arlene Naranjo; Collin Van Ryn; Douglas Russ; Derek Oldridge; Susan Kreissman; David L Baker; Marguerite Parisi; Barry L Shulkin; Harrison Bai; Sharon J Diskin; Vandana Batra; John M Maris; Julie R Park; Katherine K Matthay; Gregory Yanik
Journal:  Pediatr Blood Cancer       Date:  2017-04-06       Impact factor: 3.167

8.  The correlation between LIN28B gene potentially functional variants and Wilms tumor susceptibility in Chinese children.

Authors:  Wen Fu; Guo-Chang Liu; Zhang Zhao; Jinhong Zhu; Wei Jia; Shi-Bo Zhu; Jin-Hua Hu; Feng-Hua Wang; Jing He; Huimin Xia
Journal:  J Clin Lab Anal       Date:  2017-03-16       Impact factor: 2.352

Review 9.  Genetic susceptibility to neuroblastoma: current knowledge and future directions.

Authors:  Laura E Ritenour; Michael P Randall; Kristopher R Bosse; Sharon J Diskin
Journal:  Cell Tissue Res       Date:  2018-03-27       Impact factor: 5.249

10.  Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.

Authors:  Lihong Wang-Bishop; Zheng Chen; Ahmed Gomaa; Albert Craig Lockhart; Safia Salaria; Jialiang Wang; Keeli B Lewis; Jeffrey Ecsedy; Kay Washington; Robert Daniel Beauchamp; Wael El-Rifai
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.